Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
232results about "Depsipeptide ingredients" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Resorbable polymeric device for localized drug delivery
InactiveUS20050177118A1Good adhesionMinimizes procedural discomfortMedical devicesMammal material medical ingredientsOsteoblastHigh doses
An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. Another embodiment is arranged for the local delivery of therapeutic agent. A preferred embodiment is a porous resorbable implant, wherein the therapy delivery may be localized in nature, rather than systemic, such that higher doses at the target site may be allowed than would be tolerable by the body systemically.
Owner:KENSEY NASH CORP
Device for regeneration of articular cartilage and other tissue
InactiveUS20050074481A1Good adhesionMinimizes procedural discomfortBone implantMammal material medical ingredientsSubchondral boneOsteoblast
An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. A hydrophobic barrier exists between the regions, of this embodiment. In one embodiment, the polyelectrolytic complex transforms to hydrogel, following the implant procedure.
Owner:KENSEY NASH CORP
MODULATION OF NEUORGENESIS BY HDac INHIBITION
InactiveUS20070078083A1Maintain stabilize cognitive functionReducing a decline or decrease of cognitive functionBiocideSenses disorderNervous systemMedicine
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on an HDac inhibitory agent alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.
Owner:BRAINCELLS INC
Histone deacetylase inhibitors and cognitive applications
InactiveUS20060018921A1Enhances long-term passive avoidance memoryImprove long-termBiocideNervous disorderAcetylationPoor memory
The present invention relates to the enhancement of cognition in an individual by delivery of a histone acetylation regulator, such as a histone deacetylase inhibitor. The individual may have normal or poor memory, and the poor memory may be the result of a pathogenic condition or a non-pathogenic condition, such as with normal aging-related impairment. In a specific embodiment, enhancement of cognition occurs in an individual having a mental retardation syndrome.
Owner:BAYLOR COLLEGE OF MEDICINE
Composition and method for treating neurological disorders
InactiveUS20050037992A1Effective treatmentBetter clinical outcomeBiocideNervous disorderNervous systemFragile X chromosome
Compositions, kits and methods are provided for treating or preventing neurological disorders associated with aberrant silencing of gene expression by reestablishing the gene expression through inhibition of DNA methylation and / or histone deacetylase. The compositions and methods include administering to a patient suffering from the neurological disorder a therapeutically effective amount of a DNA methylation inhibitor, such as decitabine, preferably in combination with an effective amount of a histone deacetylase inhibitor. The compositions, kits and methods can be used to treat or present neurological disorders such as Lou Gehrig's disease, fragile X syndrome, Parkinson's disease and Alzheimer's disease.
Owner:SUPERGEN
Method for increasing therapeutic gain in radiotherapy and chemotherapy
InactiveUS20050272644A1Inhibit tumor growthReduced radiation-induced normal tissue fibrosisBiocideAntipyreticAbnormal tissue growthTumor therapy
The present invention provides compositions and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor. The compounds are capable of simultaneously stimulating the epithelium regrowth, inhibiting the fibroblast proliferation, decreasing the collagen deposit, suppressing the fibrogenic growth factor, subsiding the proinflammatory cytokine and modulating the expression of cell cycle genes, tumor suppressors and oncogenes, and are useful to increase the therapeutic gain in radiotherapy and chemotherapy, which results in decrease of skin swelling and inflammation, promotion of epithelium healing in mucosa and dermis, decrease of xerostomia, prevention / reduction of severity of plantar-palmar syndrome, prevention of tissue fibrosis, ulceration, necrosis and tumorigenesis, and increase of tumor growth inhibition and tumor therapy effectiveness.
Owner:SUNNY PHARMTECH
Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
ActiveUS20130203692A1Improve bioavailabilityImprove protectionBiocideOrganic chemistryActive agentWhole body
This invention relates to oral veterinary compositions for combating ectoparasites and endoparasites in animals, comprising at least one systemically-acting active agent in combination with a pharmaceutically acceptable carrier. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
Owner:BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC
Cancer therapy via a combination of epigenetic modulation and immune modulation
ActiveUS20160193239A1Improve immunityAnti-neoplastic effect of the immune modulating agent in the subject is enhancedOrganic active ingredientsMicrobiological testing/measurementAntiendomysial antibodiesImmune modulator
Cancer therapies that combine epigenetic modulating agent(s) with immune modulating agent(s), which were remarkably identified to provide an improved treatment regimen over single agent therapy, are disclosed. In particular embodiments, the invention provides for improved treatment of NSCLC in patients via administration of exemplary immune modulating agents anti-PD-1 antibody or anti-PD-L1 antibody, which were observed to show enhanced activity in combination with the exemplary epigenetic modulating agent 5-deoxyazacytidine. Further, expression markers of responsive neoplastic cells are also disclosed.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
InactiveUS20040132643A1Increase count rateAdequate imagingBiocideRadioactive preparation carriersLymphatic SpreadRadioactive iodine therapy
Disclosed herein are novel approaches to thyroid cancer therapy. These approaches include methods to enhance thyroid specific gene expression, for example methods to enhance expression of thyroglobulin and / or the Na<+> / I<-> symporter in thyroid cancer cells. Enhanced expression of thyroid-specific genes promotes cellular differentiation and reduces biologically aggressive behavior such as invasion and metastasis. In addition, enhanced expression of thyroglobulin and / or the Na<+> / I<31 > symporter increases the ability of thyroid cancer cells to concentrate iodine or iodide, thereby making the cells more susceptible to radioactive iodine therapy. Also disclosed herein are methods for detecting thyroid neoplasms in a subject, by administering a therapeutically effective amount of a histone deacetylase inhibitor, administering a detectable agent whose uptake or concentration in thyroid cells is increased by administration of the histone deacetylase inhibitor, and detecting the detectable agent.
Combination therapies of HDAC inhibitors and pd-1 inhibitors
ActiveUS20170327582A1Preventing and delaying recurrence of cancerExtending disease-or tumor free survival timeImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsPD-L1 inhibitorCancer prevention
Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and / or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.
Owner:HUYABIO INT LLC
Systems, methods and kits for characterizing phosphoproteomes
InactiveUS20050164324A1Quick filterImprove developmentMicrobiological testing/measurementIsotope separationPhosphorylationSystems approaches
The invention provides systems, software, methods and kits for detecting and / or quantifying phosphorylatable polypeptides and / or acetylated polypeptides in complex mixtures, such as a lysate of a cell or cellular compartment (e.g., such as an organelle). The methods can be used in high throughput assays to profile phosphoproteomes and to correlate sites and amounts of phosphorylation with particular cell states.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
A therapeutic agent for prostate cancer and malignant lymphoma containing FK228 or a salt thereof as an active ingredient, and a method for evaluating an antitumor effect of a histone deacetylase inhibitor which includes at least a step of treating a test cell with a histone deacetylase inhibitor, a step of measuring change in the expression amount of a specific gene in the test cell before and, after the treatment with the inhibitor, comparing the both expression amounts.
Owner:ASTELLAS PHARMA INC
Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
ActiveUS20130065846A1Desirable bioavailabilityFast onset of activityBiocideOrganic chemistryActive agentImproved method
This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
Owner:MERIAL INC
Use of phosphatases to treat neuroblastomas and medulloblastomas
InactiveUS20090035292A1Effective treatmentBiocideHeavy metal active ingredientsHistone deacetylaseMedicine
Disclosed herein are methods of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a phosphatase ligand in an amount effective to treat the subject. Also disclosed herein are method of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a histone deacteylase ligand in an amount effective to treat the subject.
Owner:LIXTE BIOTECH +1
Depsipeptide for therapy of kidney cancer
ActiveUS20060135413A1Confirming its antitumor effectBiocideCyclic peptide ingredientsKidney cancerBULK ACTIVE INGREDIENT
The present invention provides a therapeutic agent of kidney cancer, which comprises FK228 of the formula (I) or a salt thereof. FK228 or a salt thereof, which is an active ingredient in the present invention, shows a superior antitumor activity in vivo against kidney cancer.
Owner:HEALTH & HUMAN SERVICES THE GOVERNMENT OF THE UNITED STATES REPRESENTED BY THE SEC DEPT OF +1
Histone deacetylase inhibitors for treating degenerative diseases of the eye
Compositions and methods for treating degenerative conditions and diseases of the eye with histone deacetylase inhibitors are disclosed.
Owner:NOVARTIS AG
Psma binding ligand-linker conjugates and methods for using
ActiveUS20160151508A1Ultrasonic/sonic/infrasonic diagnosticsOrganic active ingredientsAntigenProstate specific membrane
Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
Owner:PURDUE RES FOUND INC
Device for regeneration of articular cartilage and other tissue
InactiveUS7776100B2Minimize or prevent foreign body giant cell responsesGood adhesionBone implantMammal material medical ingredientsSubchondral boneOsteoblast
An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. A hydrophobic barrier exists between the regions, of this embodiment. In one embodiment, the polyelectrolytic complex transforms to hydrogel, following the implant procedure.
Owner:KENSEY NASH CORP
Arthrodial cartilage extracellular matrix degradation inhibitor
InactiveUS20050272647A1Strong inhibitory activityBiocideAntipyreticCell-Extracellular MatrixHistone deacetylase
An agent for inhibiting articular cartilage extracellular matrix degradation of the present invention, comprising a histone deacetylase-inhibiting compound as an active ingredient, is effective for the prevention and treatment of diseases and pathological conditions involving the degradation and degeneration of the articular cartilage extracellular matrix, in particular, arthrosteitis, rheumatic arthritis, osteoarthritis, and the like.
Owner:ASTELLAS PHARMA INC
Anti-biofilm compositions and methods for using
The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.
Owner:BIOVENTURES LLC
Treatment of cancers
InactiveUS20040010043A1Eliminate side effectsIncrease doseBiocideOrganic active ingredientsSide effectCarnitine
Owner:PHARMA MAR U
Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
ActiveUS8883145B2BiocideImmunoglobulins against cytokines/lymphokines/interferonsPharmaceutical drugAnti hypertension
Owner:MEREO BIOPHARMA 5 INC
Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
The present invention provides daptomycin stereoisomeric compounds, methods and intermediates for preparing daptomycin and daptomycin stereoisomoeric compounds, as well as pharmaceutical compositions of these compounds and methods of using these compositions as antibacterial agents.
Owner:CUBIST PHARMA INC
Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
Owner:UNITED STATES OF AMERICA
Anti-biofilm compositions and methods for using
The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.
Owner:BIOVENTURES LLC
Composition and method for treating neurological disorders
InactiveUS20070254835A1Effective treatmentAddress bad outcomesBiocideNervous disorderNervous systemFragile X chromosome
Owner:SUPERGEN
Macrocyclic Compounds Useful as Inhibitors of Histone Deacetylases
The present invention provides a novel macrocyclic compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
Owner:UNIV OF COLORADO THE REGENTS OF
Biodegradable bio-absorbable material for clinical practice and method for producing the same
InactiveUS20050163822A1Deteriorate dynamic propertySuture equipmentsCyclic peptide ingredientsAbsorbable polymersUltimate tensile strength
Bio-absorbable polymers such as vascular stent and suture thread for use as materials for clinical practice have almost definite dynamic properties such as tensile strength and degradation rate for absorption. When the dynamic properties thereof are elevated, therefore, the bio-absorbable polymers turn fragile, involving slower degradation rate. When the degradation rate is elevated, further, the dynamic properties are deteriorated. Disadvantageously, such bio-absorbable polymers have limited purposes for use and limited sites for use. Thus, copolymerization of bio-absorbable polymers with a cyclic depsipeptide to form a copolymer of the ring-opened and copolymerized depsipeptide can allow the adjustment of the dynamic properties and degradation rate of the resulting copolymer depending on the content of the depsipeptide.
Owner:GOODMAN & COMPANY
Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
InactiveCN101175492ADisease diagnosisCyclic peptide ingredientsCancer cellHuman epidermal growth factor receptor
Disclosed is the use of a combination of histone deacetylase inhibitors and epidermal growth factor receptor (EGFR) inhibitors to treat cancer.
Owner:UNIV OF COLORADO THE REGENTS OF
Use of aplidine for the treatment of pancreatic cancer
InactiveUS20050004012A1Induce effectBiocideOrganic active ingredientsOncologyMetastatic pancreatic cancer
Owner:PHARMA MAR U
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com